(Q33938046)

30 July 2017

1 reference

title

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management (English)

1 reference

30 July 2017

0 references

1 reference

Millson DS

1

1 reference

30 July 2017

Tepper SJ

series ordinal

2

1 reference

30 July 2017

Rapoport AM

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Expert Opinion on Pharmacotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

1

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

391-404

1 reference

Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.3.391

21 January 2018

Identifiers

DOI

10.1517/14656566.1.3.391

1 reference

30 July 2017

1 reference